Neurocrine Biosciences Inc (NBIX.OQ)
NBIX.OQ on NASDAQ Stock Exchange Global Select Market
103.98USD
11:04am EDT
103.98USD
11:04am EDT
Change (% chg)
$0.17 (+0.16%)
$0.17 (+0.16%)
Prev Close
$103.81
$103.81
Open
$104.15
$104.15
Day's High
$105.15
$105.15
Day's Low
$103.68
$103.68
Volume
29,076
29,076
Avg. Vol
252,932
252,932
52-wk High
$106.26
$106.26
52-wk Low
$46.51
$46.51
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.29 | December | 20 Jul 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 4 | 4 | 4 | 5 |
| (2) OUTPERFORM | 6 | 6 | 6 | 6 |
| (3) HOLD | 0 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.60 | 1.60 | 1.60 | 1.55 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 8 | 131.86 | 144.00 | 103.20 | 52.16 |
| Quarter Ending Dec-18 | 8 | 112.46 | 154.30 | 91.47 | 44.02 |
| Year Ending Dec-18 | 10 | 402.40 | 444.00 | 367.89 | 164.56 |
| Year Ending Dec-19 | 10 | 606.61 | 693.00 | 530.19 | 354.78 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 9 | 0.29 | 0.50 | 0.00 | -0.16 |
| Quarter Ending Dec-18 | 9 | 0.06 | 0.51 | -0.28 | -0.29 |
| Year Ending Dec-18 | 10 | -0.26 | 0.16 | -0.95 | -1.44 |
| Year Ending Dec-19 | 10 | 1.32 | 2.30 | 0.18 | 0.06 |
| LT Growth Rate (%) | 1 | 148.70 | 148.70 | 148.70 | 47.90 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-18 | 63.05 | 71.09 | 8.04 | 12.75 |
| Quarter Ending Dec-17 | 87.77 | 94.52 | 6.75 | 7.69 |
| Quarter Ending Sep-17 | 29.85 | 60.77 | 30.92 | 103.58 |
| Quarter Ending Jun-17 | 0.66 | 6.34 | 5.67 | 854.21 |
| Quarter Ending Mar-17 | 3.75 | 0.00 | 3.75 | 100.00 |
| Earnings (per share) | ||||
| Quarter Ending Mar-18 | -0.30 | -0.47 | 0.17 | -55.12 |
| Quarter Ending Dec-17 | 0.18 | 0.07 | 0.11 | 61.43 |
| Quarter Ending Sep-17 | -0.48 | -0.13 | 0.35 | -72.96 |
| Quarter Ending Jun-17 | -0.66 | -0.68 | 0.02 | -2.64 |
| Quarter Ending Mar-17 | -0.74 | -0.90 | 0.16 | -22.32 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 131.86 | 131.86 | 131.86 | 124.44 | 52.16 |
| Quarter Ending Dec-18 | 112.46 | 112.46 | 114.67 | 113.94 | 44.02 |
| Year Ending Dec-18 | 402.40 | 406.60 | 408.37 | 401.18 | 164.56 |
| Year Ending Dec-19 | 606.61 | 616.31 | 618.03 | 627.34 | 354.78 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 0.29 | 0.29 | 0.29 | 0.25 | -0.16 |
| Quarter Ending Dec-18 | 0.06 | 0.06 | 0.08 | 0.08 | -0.29 |
| Year Ending Dec-18 | -0.26 | -0.22 | -0.20 | -0.23 | -1.44 |
| Year Ending Dec-19 | 1.32 | 1.42 | 1.43 | 1.55 | 0.06 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-18 | 0 | 1 | 0 | 2 |
| Year Ending Dec-19 | 0 | 1 | 0 | 2 |
| Earnings | ||||
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-18 | 0 | 1 | 0 | 2 |
| Year Ending Dec-19 | 0 | 1 | 0 | 2 |
Earnings vs. 
Estimates- BRIEF-Neurocrine Biosciences Q1 Loss Per Share $0.47
- FDA needs more time to review AbbVie, Neurocrine's uterine pain drug
- UPDATE 2-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug
- FDA needs more time to review AbbVie, Neurocrine's uterine pain drug
- CORRECTED-UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug